Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Evolent Health, Inc.
Report date July 01, 2023 · Filed April 26, 2024
Section 16 reporting ended · disclosed 2024-04-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 136,331 |
Reported balance
After 2023-07-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-07-01 · Grant · Acquired 9,000 · Balance 136,331 F1: This Form 4 is being filed late due to an administrative error. F2: Represents restricted stock units granted to Mr. Tutewohl pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. On July 31, 2023, Mr. Tutewohl's last day of employment with the company, 3,000 of these RSUs vested and the remaining 6,000 were forfeited, in accordance with the terms of Mr. Tutewohl's severance and change in control agreement. Mr. Tutewohl ceased to be an officer of the company on July 3, 2023. F3: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 is being filed late due to an administrative error.
F2: Represents restricted stock units granted to Mr. Tutewohl pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. On July 31, 2023, Mr. Tutewohl's last day of employment with the company, 3,000 of these RSUs vested and the remaining 6,000 were forfeited, in accordance with the terms of Mr. Tutewohl's severance and change in control agreement. Mr. Tutewohl ceased to be an officer of the company on July 3, 2023.
F3: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2021 Filed Mar 4, 2021 01:49 UTC | Evolent Health, Inc. EVH · Entity 5492 | GrantClass A Common Stock | 31,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-21-000034 · wf-form4_161482253003982.xml · nonDerivative · entry 1 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,046 F1 · security: Includes restricted stock units granted to Mr. Tutewohl pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest at a rate of 25% annually beginning March 1, 2022. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 3s previously filed with the Securities and Exchange Commission. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.